Cohance Lifesciences Peer Comparison

NSE: COHANCE | BSE: 543064

₹453.85

₹-7.95 (-1.72%)

As on 22-Oct-2026IST

Market cap

₹17,443 Cr

Revenue (TTM)

₹2,142 Cr

P/E Ratio

164.2

P/B Ratio

4.5

Div. Yield

0 %

Edit

	Cohance Lifesciences	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	17,443	30,160	25,975	26,309	23,777
Revenue (₹ Cr)	2,142	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	58.53	414.00	-371.81	387.35	288.22
Net Margin (%)	2.69	11.23	-3.93	26.01	14.79
RoE (%)	3.29	8.38	-3.85	25.18	29.77
Price to Earnings	164.20	73.74	--	68.12	82.50
Price-To-Book	4.53	5.99	3.24	15.25	17.71

Income Statement (₹ Cr)

	Cohance Lifesciences	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	2,141.50	3,564.00	9,205.28	1,461.80	1,935.80
Total Income	2,173.67	3,686.00	9,449.59	1,489.25	1,948.58
Total Expenditure	1,825.36	2,792.00	8,195.15	919.25	1,485.56
EBITDA	316.14	772.00	1,010.13	542.56	450.24
Depreciation	191.73	226.00	857.51	37.68	50.83
EBIT	124.41	546.00	152.62	504.88	399.41
Interest	33.80	217.00	342.73	3.77	40.84
Other Income	32.17	122.00	244.31	27.45	12.78
Exceptional Items	-21.37	12.00	-216.88	0.00	0.00
Profit before Tax	101.41	463.00	-162.68	528.56	371.35
Provision for Tax	42.88	49.00	209.13	141.21	83.14
Profit after Tax	58.53	414.00	-371.81	387.35	288.22

	Cohance Lifesciences	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	3,911.29	4,940.00	8,162.62	1,653.56	1,288.82
Minority Interest	47.70	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	1,049.88	1,712.00	5,044.14	42.40	202.03
Current Liabilities	645.93	1,622.00	4,758.28	230.82	835.87
Total Liabilities	5,727.00	8,578.00	17,723.32	1,983.96	2,326.71

	Cohance Lifesciences	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	3,581.55	5,343.00	10,211.52	1,026.85	519.60
Current Assets	1,796.26	2,606.00	7,191.66	881.27	1,681.81
Total Assets	5,727.00	8,578.00	17,723.32	1,983.96	2,326.71
Total Debt*	169.67	2,125.00	5,495.48	26.49	259.37
Net Current Assets	1,150.33	984.00	2,433.38	650.46	845.94
Contingent Liabilities	53.31	768.26	95.72	17.25	19.09

	Cohance Lifesciences	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	368.32	390.00	1,652.60	292.17	205.05
Cash Flow from Investing Activities	-254.57	-241.00	-826.03	-265.94	-409.72
Cash from Financing Activities	-165.15	-54.00	-38.98	4.10	283.07
Net Cash Inflow / Outflow	-51.40	95.00	787.59	30.33	78.39

	Cohance Lifesciences	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	6.12	6.79	1.24	32.42	29.22
ROE (%)	3.29	8.38	-3.85	25.18	29.77
ROA (%)	1.34	4.94	-2.21	21.93	24.77
EBIT Margin (%)	5.81	15.32	1.66	34.54	20.63
Net Margin (%)	2.69	11.23	-3.93	26.01	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Cohance Lifesciences	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	-19.79	18.37	0.78	40.90	46.65
EBIT Growth (%)	-79.38	252.26	-70.53	124.50	62.13
Net Profit Growth (%)	-87.14	377.85	-1,383.43	104.15	89.49
EPS Growth (%)	-81.67	1,001.33	-484.84	42.32	78.60
Book Value Growth (%)	9.14	13.47	0.33	26.03	144.31

	Cohance Lifesciences	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	137.51	75.69	-83.01	68.12	81.23
Price / Book Value	4.53	5.99	3.24	15.25	17.71
Dividend Yield (%)	0.00	0.00	0.00	0.08	0.10
EV/EBITDA	54.68	40.96	29.81	48.13	52.62
Market Cap (₹ Cr)	11,550.78	19,071.62	18,108.89	20,944.75	12,753.19

	Cohance Lifesciences	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.01	0.31	0.53	0.02	0.11
Short term debt to equity ratio	0.02	0.09	0.09	0.02	0.05
Current Ratio	2.78	1.61	1.51	3.82	2.01
Quick Ratio	1.91	1.06	0.87	2.82	1.14
Interest Coverage	4.00	3.13	0.53	141.16	10.09

	Cohance Lifesciences	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	31.80	16.50	23.44	24.80	26.28
Asset Turnover	0.49	0.43	0.55	0.83	1.66
Receivable days	116.90	58.75	78.20	88.98	40.13
Inventory Days	82.83	75.82	93.30	56.04	60.29
Payable days	153.58	186.21	226.14	99.95	232.47
Cash Conversion Cycle	46.15	-51.64	-54.64	45.07	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.